Invention Grant
- Patent Title: MASP inhibitory compounds and uses thereof
-
Application No.: US17138447Application Date: 2020-12-30
-
Publication No.: US11667675B2Publication Date: 2023-06-06
- Inventor: Donald Bierer , Ingo Flamme , Dmitry Zubov , Thomas Neubauer , Adrian Tersteegen , Cathleen Juhl , Marie Glatz , Jan Dreher , Simon Holton , Carsten Terjung , Lars Baumann , Thorsten Poethko , Jiancheng Xiong , Yibo Qiu
- Applicant: Bayer Aktiengesellschaft , Bayer Pharma Aktiengesellschaft
- Applicant Address: DE Leverkusen
- Assignee: Bayer Aktiengesellschaft,Bayer Pharma Aktiengesellschaft
- Current Assignee: Bayer Aktiengesellschaft,Bayer Pharma Aktiengesellschaft
- Current Assignee Address: DE Leverkusen; DE Berlin
- Agency: Morrison & Foerster LLP
- Priority: WO TCN2019085791 2019.05.07
- Main IPC: C07K7/08
- IPC: C07K7/08 ; A61P13/12 ; A61K38/10 ; A61K45/06
Abstract:
The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.
Public/Granted literature
- US20210246166A1 MASP INHIBITORY COMPOUNDS AND USES THEREOF Public/Granted day:2021-08-12
Information query
